Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.47 |
| ▸ | FLT1 | P17948 | 1/20 | 0.47 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | G6PD | P11413 | 1/20 | 0.44 |
| ▸ | CRHBP | P24387 | 1/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2589956 | 0.94 | LMNA (0.52) | LMNAMEN1KMT2ATDP1GAA | |
| SCHEMBL6745891 | 0.88 | GAA (0.55) | LMNAMEN1KMT2ATDP1GAA | |
| SCHEMBL31305210 | 0.87 | PDGFRB (0.51) | LMNATDP1ALDH1A1MAPTPDGFRB | |
| SCHEMBL11778508 | 0.86 | LMNA (0.53) | LMNAMEN1KMT2ATDP1GAA | |
| SCHEMBL1784674 | 0.86 | LMNA (0.53) | LMNAMEN1KMT2ATDP1ALDH1A1 | |
| SCHEMBL1787616 | 0.86 | MEN1 (0.50) | LMNAMEN1KMT2ATDP1ALDH1A1 | |
| SCHEMBL1785981 | 0.86 | MEN1 (0.47) | LMNAMEN1KMT2ATDP1GAA | |
| SCHEMBL8902175 | 0.86 | CHEK1 (0.51) | LMNAMEN1KMT2ATDP1GAA | |
| SCHEMBL2903296 | 0.86 | TDP1 (0.53) | LMNAMEN1KMT2ATDP1GAA | |
| SCHEMBL1786813 | 0.86 | MEN1 (0.51) | LMNAMEN1KMT2ATDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| WO-2024220937-A2 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| US-20130203730-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2013-08-08 | — | — | US | disclosed |
| EP-2607357-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | Astrazeneca AB (SE) | 2013-06-26 | — | — | EP | disclosed |
| US-8440681-B2 | 2-biphenylamino-4-aminopyrimidine derivatives as kinase inhibitors | IRM LLC (BM) | 2013-05-14 | — | — | US | disclosed |
| US-20120115845-A1 | THERAPEUTIC AGENTS | ALLEN JACK MCQUEEN (GB) | 2012-05-10 | — | — | US | disclosed |
| US-20110124621-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2011-05-26 | — | — | US | disclosed |
| US-20100298295-A1 | 2-BIPHENYLAMINO-4-AMINOPYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2010-11-25 | — | — | US | disclosed |
| EP-2205576-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2010-07-14 | — | — | EP | disclosed |
| EP-2190826-A2 | 2-BIPHENYLAMINO-4-AMINOPYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2010-06-02 | — | — | EP | disclosed |
| US-20090186870-A1 | Therapeutic Agents - 802 | ASTRAZENECA AB (SE) | 2009-07-23 | — | — | US | disclosed |
| WO-2009047558-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009032668-A2 | 2 -BIPHENYLAMINO-4 -AMINOPYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, CSNK2A1, CSNK2A2 | LMNA 2666/4885MEN1 4258/4885KMT2A 242/4885 |
| US-20130203730-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | GPR119, GHSR, GLP1R | LMNA 4721/4885MEN1 2250/4885KMT2A 1721/4885 |
| US-20120115845-A1 | THERAPEUTIC AGENTS | GPR119, MC2R, MC4R | LMNA 4327/4885MEN1 692/4885KMT2A 3139/4885 |
| US-20090186870-A1 | Therapeutic Agents - 802 | GPR119, SLC5A2, MC2R | LMNA 4113/4885MEN1 1253/4885KMT2A 2304/4885 |
| US-20100298295-A1 | 2-BIPHENYLAMINO-4-AMINOPYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IGF1R, IGFBP1, IRS1 | LMNA 3562/4885MEN1 3095/4885KMT2A 1649/4885 |
| US-20110124621-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | GPR119, GHSR, GLP1R | LMNA 4721/4885MEN1 2250/4885KMT2A 1721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.